- Home
- ITIC vs INBX Comparison
ITIC vs INBX Comparison
Compare ITIC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- INBX
- Stock Information
- Founded
- ITIC 1972
- INBX 2010
- Country
- ITIC United States
- INBX United States
- Employees
- ITIC N/A
- INBX N/A
- Industry
- ITIC Specialty Insurers
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ITIC Finance
- INBX Health Care
- Exchange
- ITIC Nasdaq
- INBX Nasdaq
- Market Cap
- ITIC 517.1M
- INBX 430.2M
- IPO Year
- ITIC N/A
- INBX 2020
- Fundamental
- Price
- ITIC $263.43
- INBX $28.70
- Analyst Decision
- ITIC
- INBX Hold
- Analyst Count
- ITIC 0
- INBX 2
- Target Price
- ITIC N/A
- INBX N/A
- AVG Volume (30 Days)
- ITIC 32.2K
- INBX 186.7K
- Earning Date
- ITIC 11-03-2025
- INBX 11-13-2025
- Dividend Yield
- ITIC 5.98%
- INBX N/A
- EPS Growth
- ITIC 25.49
- INBX N/A
- EPS
- ITIC 17.49
- INBX N/A
- Revenue
- ITIC $269,460,000.00
- INBX $1,400,000.00
- Revenue This Year
- ITIC N/A
- INBX $563.00
- Revenue Next Year
- ITIC N/A
- INBX $230.77
- P/E Ratio
- ITIC $15.12
- INBX N/A
- Revenue Growth
- ITIC 15.27
- INBX N/A
- 52 Week Low
- ITIC $190.20
- INBX $10.81
- 52 Week High
- ITIC $290.40
- INBX $39.27
- Technical
- Relative Strength Index (RSI)
- ITIC 55.31
- INBX 40.91
- Support Level
- ITIC $259.05
- INBX $31.28
- Resistance Level
- ITIC $266.06
- INBX $39.27
- Average True Range (ATR)
- ITIC 6.83
- INBX 2.96
- MACD
- ITIC -0.80
- INBX -0.81
- Stochastic Oscillator
- ITIC 48.57
- INBX 10.31
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.